slide1
Download
Skip this Video
Download Presentation
What is the optimal sequence of therapies for stage II-III adenocarcinoma of the proximal stomach?

Loading in 2 Seconds...

play fullscreen
1 / 14

What is the optimal sequence of therapies for stage II-III adenocarcinoma of the proximal stomach? - PowerPoint PPT Presentation


  • 86 Views
  • Uploaded on

What is the optimal sequence of therapies for stage II-III adenocarcinoma of the proximal stomach? Peri -operative chemotherapy . Josep Tabernero, MD PhD Medical Oncology Department Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology Barcelona.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' What is the optimal sequence of therapies for stage II-III adenocarcinoma of the proximal stomach?' - zytka


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1
What is the optimal sequence of therapies for stage II-III adenocarcinoma of the proximal stomach?

Peri-operative chemotherapy 

Josep Tabernero, MD PhD

Medical Oncology Department

Valld’Hebron University Hospital &

Valld’Hebron Institute of Oncology

Barcelona

Great Debates & Updates in GI Malignancies

NY, March 29th, 2014

slide2

GASTRIC meta-analysis on individual data: Survival

OS, CT + surgery

OS, surgery alone

DFS, CT + surgery

DFS, surgery alone

Survival proportion

77% of the recurrences

occurred during the first 3 years

OS HR = 0.81

95% CI = 0.74-0.87

p = 0.03

Follow-up (years)

Gastric cancer meta-analysis. JAMA 2010;303:1729-37

slide3

But adjuvant chemotherapy (radiotherapy) cannot be administered to all patients…

50 - 70% may receive adjuvant treatment but tolerance is poor:

- Treatment delays

- Dose reductions

- Early termination

Surgery

“in the Real life”

BUT:

- Delayed surgical recovery

- Poor food intake

- Dumping syndrome

- Poor performance status

- Treatment refusal

~30 - 50%?

Interest of pre/peri-operative treatment in resectable but infiltrating tumor

slide4

Rationale for peri-operative or pre-operative chemotherapy

  • To offer chemotherapy treatment to a larger number of patients
  • To downsize/downstage the tumor
  • To facilitate the surgery
  • To decrease the risk of local recurrence and distant metastasis
  • To increase the overall survival
  • To offer a better safety profile and treatment tolerability
  • To offer a more effective treatment (compliance)
perioperative or pre operative chemotherapy
Perioperative or pre-operative chemotherapy

Preoperative chemotherapy

Postoperative chemotherapy

Surgery

R

Surgery

Cunningham D et al. N Engl J Med 2006;355:11-20; Ychou Met al. J Clin Oncol 2011;29:1715-1721; Schuhmacher C et al. J Clin Oncol 2010;28:5210-5218.

stage inclusion criteria
Stage – Inclusion criteria

Cunningham D et al. N Engl J Med 2006;355:11-20; Ychou Met al. J Clin Oncol 2011;29:1715-1721; Schuhmacher C et al. J Clin Oncol 2010;28:5210-5218.

pathology results
Pathology Results

Cunningham D et al. N Engl J Med 2006;355:11-20; Ychou Met al. J Clin Oncol 2011;29:1715-1721; Schuhmacher C et al. J Clin Oncol 2010;28:5210-5218.

overall survival
Overall Survival

Cunningham D et al. N Engl J Med 2006;355:11-20; Ychou Met al. J Clin Oncol 2011;29:1715-1721; Schuhmacher C et al. J Clin Oncol 2010;28:5210-5218.

magic survival
MAGIC - Survival

Cunningham D et al. N Engl J Med 2006;355:11-20

meta analysis of pre peri operative treatment
Meta-analysis of pre/peri-operative treatment

Survival

Ge L et al. World J Gastroenterol 2012;18:7384-7393

slide12

Pre/perioperative treatment –

Take home messages

  • Feasible and safe
  • Compliance: 90% preoperative, 50-70% post-operative
  • Significantly downstage/downsize the tumor and increase R0 resections
  • Does not increase perioperative morbidity and mortality
  • Significantly improves OS (13% at 5-yr in the largest studies)
magic b sto 03
MAGIC – B – STO-03

Randomised

ECX

Repeated every 21 days for 3cycles

ECX + Bevacizumab Repeated every 21 days for 3cycles

Surgery

5 wk break from last pre-op chemo

(8 wk break from last bevacizumab)

6-10 wk break before post-op chemo

ECX

Repeated every 21 days for 3cycles

ECX + Bevacizumab

Repeated every 21 days for 3cycles

Maintenance Bevacizumab

Every 21 days for 6 doses

critics

³

“MAGIC”(3xECC)

15

Lymph nodes

45 Gy/25

fx

+

no

splenectomy

capecitabine

dd

Epirubicine

/

Cisplatin

/Capecitabine

cisplatin

1

-

5x pw

3D

-

CRT/IMRT

CRITICS

Preoperative chemotherapy

3x ECC q 3wks

D1 + surgery

3x ECC q 3wks

QoL

R

Preoperative chemotherapy

3x ECC q 3wks

D1 + surgery

Chemoradiation

Tissue

banking

  • Stratified for:
  • Centre
  • Histological type
  • Localisation of tumour
ad